Summary
The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? This report will tell you.
This in-depth market analysis examines prospects for antipsychotic drugs right through to 2012, including sales forecasts for leading products. The antipsychotics market will face decreasing growth throughout the forecast period, due to the patent expiry of leading blockbuster drugs. Safety concerns over the current antipsychotics along with high prices, will also contribute to decreased growth in this market.
The antipsychotics market currently contains four blockbuster drugs; Zyprexa, Risperdal, Seroquel and Abilify. Visiongain predicts that a fifth drug will also reach blockbuster status by 2008. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.
According to the National Alliance for Research on Schizophrenia and Depression, approximately 22.1 per cent of American adults (approximately 64 million people) suffer from a diagnosable mental illness in any given year. Of these, it is estimated that over 2 million suffer from schizophrenia.
Similarly, approximately 18.8 million people have a depressive disorder, with approximately 2.3 to 3 million suffering from bipolar disorder.
The Antipsychotic Drugs Market Insight and Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include primary research unavailable elsewhere, in-house and industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.
In particular, The Antipsychotics Market concentrates on the following essential aspects of the market:
- Discussion of the current pharmaceutical market
- Forecast of the worldwide pharmaceutical market from 2007-2012
- Drivers and restraints facing the antipsychotics market
- Opportunities and threats facing the antipsychotics market
- Growth of the antipsychotic drugs market between 2007-2012
- Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012
- The potential of generics manufacturers to penetrate this market
- Pipeline developments with blockbuster potential
- Currently marketed drugs with blockbuster potential
- Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for antipsychotic drugs from 2007-2012
- To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2007-2012
- To determine key activities of leading companies
- To discover "hot" pipeline developments and up-and-coming products
- To determine the forces that influence the market for antipsychotic products:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats (SWOT analysis)
- To find out where the antipsychotics market is heading - both technologically and commercially
The future of current and potential anti-psychotic blockbusters is vitally important to each company. Off label allocation has seen companies write off funds for possible legal actions. Zyprexa-maker Lilly set aside $1.2 billion to settle 31,000 claims and still faces 1,200 cases and a federal probe.
Bristol-Myers Squibb, maker of Abilify, agreed to pay $515 million last year, in part to settle off-label marketing allegations; the firms also face thousands of additional claims. AstraZeneca has 8,000 suits pending for Seroquel.
This report concentrates on arguably the most exciting challenge facing the anti-psychotic industry and regulators: how to adapt medicine to patient sub-populations and emerging regulatory demands, improving safety and efficacy markedly. No pharmaceutical company can afford to ignore those issues.
|
